Supporting this, we and others have shown that 18F‐PI‐2620 tau‐PET shows elevated in vivo binding in 4R‐tau target regions in the basal ganglia in patients with PSP and CBS.10, 11. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.